Psilocybin Aims for Mainstream as a Psychedelic Treatment for Depression

Psilocybin biopharma companies are pushing psychedelics toward mainstream medicine for depression by reframing “magic mushroom” treatments as legitimate clinical products. The reporting centers on the mood and positioning around psychedelic industry events, where scientists, investors, and clinicians discuss therapy models and the commercialization effort while trying to shed countercultural branding. Scenes described include discussion of long sessions and the idea of a therapist on standby, alongside broader cultural references. The piece is aimed at explaining how the industry is building credibility and momentum, even while emphasizing ongoing uncertainty around how these therapies should be delivered and understood.